-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Morgan Stanley Lowers ADC Therapeutics (NYSE:ADCT) Price Target to $5.00
Morgan Stanley Lowers ADC Therapeutics (NYSE:ADCT) Price Target to $5.00
ADC Therapeutics (NYSE:ADCT – Get Rating) had its target price trimmed by Morgan Stanley from $7.00 to $5.00 in a research note published on Tuesday morning, Benzinga reports. The brokerage currently has an equal weight rating on the stock.
A number of other equities analysts have also commented on the company. Capital One Financial assumed coverage on ADC Therapeutics in a research note on Tuesday, December 6th. They set an overweight rating and a $12.00 price target for the company. Bank of America lowered ADC Therapeutics from a buy rating to a neutral rating and lowered their price objective for the company from $14.00 to $7.00 in a research note on Tuesday, November 8th. Royal Bank of Canada lowered their price objective on ADC Therapeutics from $25.00 to $20.00 and set an outperform rating for the company in a research note on Wednesday, November 9th. Finally, HC Wainwright lowered their price objective on ADC Therapeutics from $21.00 to $20.00 and set a buy rating for the company in a research note on Wednesday, January 4th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, ADC Therapeutics currently has a consensus rating of Moderate Buy and an average target price of $11.50.
Get ADC Therapeutics alerts:ADC Therapeutics Stock Performance
NYSE ADCT opened at $4.68 on Tuesday. The firm has a market cap of $359.47 million, a price-to-earnings ratio of -2.17 and a beta of 0.95. The company has a quick ratio of 4.82, a current ratio of 5.00 and a debt-to-equity ratio of 0.92. The business has a 50-day moving average price of $3.76 and a 200-day moving average price of $5.37. ADC Therapeutics has a twelve month low of $2.69 and a twelve month high of $17.89.
ADC Therapeutics (NYSE:ADCT – Get Rating) last announced its quarterly earnings results on Tuesday, November 8th. The company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.14). ADC Therapeutics had a negative net margin of 105.67% and a negative return on equity of 120.99%. The firm had revenue of $76.32 million for the quarter, compared to the consensus estimate of $55.61 million. As a group, equities research analysts predict that ADC Therapeutics will post -2.05 EPS for the current fiscal year.Institutional Investors Weigh In On ADC Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of the business. Values First Advisors Inc. purchased a new stake in shares of ADC Therapeutics in the fourth quarter worth approximately $40,000. Hennion & Walsh Asset Management Inc. raised its holdings in shares of ADC Therapeutics by 14.2% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 58,869 shares of the company's stock worth $226,000 after buying an additional 7,337 shares during the period. Trexquant Investment LP purchased a new stake in shares of ADC Therapeutics in the third quarter worth approximately $226,000. Prosight Management LP purchased a new stake in shares of ADC Therapeutics in the third quarter worth approximately $1,194,000. Finally, Blue Owl Capital Holdings LP purchased a new stake in shares of ADC Therapeutics in the third quarter worth approximately $3,536,000. 75.56% of the stock is currently owned by hedge funds and other institutional investors.
ADC Therapeutics Company Profile
(Get Rating)
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL).
See Also
- Get a free copy of the StockNews.com research report on ADC Therapeutics (ADCT)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab's First U.S. Launch Send Stock Into Stratosphere?
- 3 Retail Stocks Ringing the Register in 2023
Receive News & Ratings for ADC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
ADC治疗公司(纽约证券交易所代码:ADCT-GET评级)据Benzinga报道,摩根士丹利在周二上午发布的一份研究报告中将其目标价从7.00美元下调至5.00美元。该经纪公司目前对该股的评级为同等权重。
其他一些股票分析师也对该公司发表了评论。Capital One Financial在12月6日星期二的一份研究报告中承担了对ADC治疗公司的报道。他们为该公司设定了增持评级和12.00美元的目标价。11月8日,周二,美国银行在一份研究报告中将ADC治疗公司的评级从买入下调至中性,并将该公司的目标价从14.00美元下调至7.00美元。11月9日,加拿大皇家银行在一份研究报告中将他们对ADC治疗公司的目标价从25.00美元下调至20.00美元,并为该公司设定了表现优于大盘的评级。最后,HC Wainwright在1月4日星期三的一份研究报告中将他们对ADC治疗的目标价从21.00美元下调至20.00美元,并在一份研究报告中为该公司设定了买入评级。两名投资分析师对该股的评级为持有,四名分析师对该股的评级为买入。根据MarketBeat的数据,ADC治疗公司目前的共识评级为中等买入,平均目标价为11.50美元。
到达ADC治疗公司警报:ADC治疗公司股票表现
纽约证交所ADCT周二开盘报4.68美元。该公司市值为3.5947亿美元,市盈率为-2.17倍,贝塔系数为0.95。该公司的速动比率为4.82,流动比率为5.00,债务权益比率为0.92。该业务的50日移动均线价格为3.76美元,200日移动均线价格为5.37美元。ADC治疗公司的12个月低点为2.69美元,12个月高位为17.89美元。
ADC治疗公司(纽约证券交易所代码:ADCT-GET评级)最近一次公布季度收益结果是在11月8日星期二。该公司公布了该季度每股收益(0.65美元),低于分析师普遍预期的(0.51美元)和(0.14美元)。ADC治疗公司的净利润率为负105.67%,净资产回报率为负120.99%。该公司本季度营收为7632万美元,而市场普遍预期为5561万美元。作为一个整体,股票研究分析师预测,ADC治疗公司本财年的每股收益将达到2.05欧元。机构投资者对ADC治疗公司的看法
几家对冲基金和其他机构投资者最近调整了对该公司的持股。Values First Advisors公司在第四季度购买了价值约40,000美元的ADC治疗公司的新股份。Hennion&Walsh资产管理公司在第四季度将其持有的ADC治疗公司的股票增加了14.2%。Hennion&Walsh Asset Management Inc.现在持有58,869股该公司股票,价值226,000美元,在此期间又购买了7,337股。Trexquant Investment LP在第三季度购买了ADC治疗公司的新股份,价值约226,000美元。Prosight Management LP在第三季度购买了ADC治疗公司的新股份,价值约119.4万美元。最后,Blue Owl Capital Holdings LP在第三季度购买了ADC治疗公司价值约3,536,000美元的新股份。75.56%的股票目前由对冲基金和其他机构投资者持有。
ADC治疗公司简介
(获取评级)
ADC Treateutics SA是一家商业阶段的生物技术公司,为血液系统恶性肿瘤和实体肿瘤患者开发抗体药物结合物(ADC)。其旗舰产品ZYNLONTA正在进行第二阶段的临床试验,用于治疗复发或难治性弥漫性大B细胞淋巴瘤(DLBCL)和滤泡性淋巴瘤;第三阶段临床试验联合利妥昔单抗治疗二线移植不合格患者中的复发或难治性DLBCL;以及第一阶段临床试验,用于治疗复发或难治性非霍奇金淋巴瘤(NHL)。
另请参阅
- 免费获取StockNews.com关于ADC治疗的研究报告(ADCT)
- 柔顺治疗公司的差距增加了34%:未来还会有更多的好处吗?
- 2023年初裁员将如何影响这5只生物科技股?
- Baudax Bio投资者在经历了70%的飙升后,痛苦是否已经结束?
- 火箭实验室的首次美国发射将把斯托克送入平流层吗?
- 2023年响亮登场的3只零售股
接受ADC治疗日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对ADC治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧